Evidence map›Paper›PMID 39504242›Full record

ArticleCell reports2024

An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo.

Nian E Zhou, Su Tang, Xuelin Bian, Maloy K Parai, Inna V Krieger, Armando Flores, Pradeep K Jaiswal, Radha Bam, Jeremy L Wood, Zhe Shi and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Anti-Biofilm Activity of (+)-Endo-Borneol AgainstPlants (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Nian E ZhouDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
Su TangDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
Xuelin BianDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
Maloy K ParaiDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
Inna V KriegerDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
Armando FloresDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
Pradeep K JaiswalDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
Radha BamDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
Jeremy L WoodDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
Zhe ShiDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
Laura J StevensDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Trevor ScobeyDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Meghan V DiefenbacherDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Fernando R MoreiraDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Thomas J BaricDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Arjun AcharyaDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
Joonyoung ShinDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
Manish M RathiDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA.
Karen C WolffCalibr-Skaggs Institute for Innovative Medicine, La Jolla, CA 92037, USA.
Laura RivaCalibr-Skaggs Institute for Innovative Medicine, La Jolla, CA 92037, USA.
Malina A BakowskiCalibr-Skaggs Institute for Innovative Medicine, La Jolla, CA 92037, USA.
Case W McNamaraCalibr-Skaggs Institute for Innovative Medicine, La Jolla, CA 92037, USA.
Nicholas J CatanzaroDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Rachel L GrahamDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
David C SchultzDepartment of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, USA.
Sara CherryDepartment of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Yoshihiro KawaokaInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA.
Peter J HalfmannInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA.
Ralph S BaricDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mark R DenisonDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Timothy P SheahanDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: sheahan@email.unc.edu.
James C SacchettiniDepartment of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77840, USA. Electronic address: sacchett@tamu.edu.

Funding

Research Project 1: Coronavirus antiviral lead development and combination testingU19AI171292 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CAMERON, CRAIG E. · 2022 to 2022
$65.5M
Regulation of Lipid Droplets and FOXO3 in Intestinal Epithelial Cell ProliferatioR01CA160809 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI SAVKOVIC, SUZANA D. · 2012 to 2015
$1.2M
NCI NIH HHS R01 CA160809NIAID NIH HHS U19 AI171292
6 · The paper itself

Abstract

Safe, effective, and low-cost oral antiviral therapies are needed to treat those at high risk for developing severe COVID-19. To that end, we performed a high-throughput screen to identify non-peptidic, non-covalent inhibitors of the SARS-CoV-2 main protease (Mpro), an essential enzyme in viral replication. NZ-804 was developed from a screening hit through iterative rounds of structure-guided medicinal chemistry. NZ-804 potently inhibits SARS-CoV-2 Mpro (0.009 μM IC

Indexed as

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentSARS-CoV-2Virus ReplicationAdministration, OralAnimalsCell LineChlorocebus aethiopsCoronavirus 3C ProteasesCricetinaeDisease Models, AnimalFemaleHumansMesocricetusMice3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesProtease Inhibitorsantiviralbroad-spectrumcoronavirusCP: Microbiologyemerging virusesPaxlovidproteaseSARS-CoV-2therapeutics

Identifiers

PMID39504242
PMCPMC12180444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.